$CRYM
Cryomass Technologies, Inc.

2022 Q3 Form 10-Q Financial Statement

#000121390022046798 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $496.7K $926.6K $1.754M
YoY Change -40.15% -58.1% 181.94%
% of Gross Profit
Research & Development $2.031K $1.365K $17.12K
YoY Change
% of Gross Profit
Depreciation & Amortization $21.84K $21.83K $21.83K
YoY Change 0.05%
% of Gross Profit
Operating Expenses $1.254M $1.416M $2.128M
YoY Change -39.03% -46.3%
Operating Profit -$1.254M -$1.416M -$2.128M
YoY Change -39.03% -46.3%
Interest Expense $25.41K -$14.18K -$24.51K
YoY Change -104.48% -96.18% -85.4%
% of Operating Profit
Other Income/Expense, Net $25.41K -$14.17K -$24.52K
YoY Change -104.48% -96.18%
Pretax Income -$1.228M -$1.430M -$2.152M
YoY Change -53.18% -52.45% 84.98%
Income Tax
% Of Pretax Income
Net Earnings -$1.228M -$1.430M -$2.152M
YoY Change -48.25% -48.35% 105.58%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01 -$10.86K
COMMON SHARES
Basic Shares Outstanding 201.5M shares 200.6M shares 198.3M shares
Diluted Shares Outstanding 202.0M shares 200.6M shares 198.3M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.130M $2.188M $3.594M
YoY Change 1217.51% 407.3% 443.44%
Cash & Equivalents $3.130M $2.188M $3.594M
Short-Term Investments
Other Short-Term Assets $136.6K $66.84K $73.18K
YoY Change -98.16% -99.07% -98.96%
Inventory
Prepaid Expenses $136.6K $66.84K
Receivables
Other Receivables
Total Short-Term Assets $3.266M $2.255M $3.667M
YoY Change -61.53% -73.3% -55.34%
LONG-TERM ASSETS
Property, Plant & Equipment $349.6K $349.6K $233.6K
YoY Change 158.95%
Goodwill $1.190M $1.190M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $9.785M $9.773M $9.659M
YoY Change 81.69% 85.36%
TOTAL ASSETS
Total Short-Term Assets $3.266M $2.255M $3.667M
Total Long-Term Assets $9.785M $9.773M $9.659M
Total Assets $13.05M $12.03M $13.33M
YoY Change -5.95% -12.31% 62.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.235M $1.089M $1.365M
YoY Change -60.48% -55.2% -29.61%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.235M $1.089M $1.365M
YoY Change -77.73% -65.62% -70.92%
LONG-TERM LIABILITIES
Long-Term Debt $2.000M $239.6K $208.3K
YoY Change -51.6% -95.14% 150.01%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.000M $239.6K $208.3K
YoY Change -51.6% -95.14% 150.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.235M $1.089M $1.365M
Total Long-Term Liabilities $2.000M $239.6K $208.3K
Total Liabilities $3.235M $1.329M $1.573M
YoY Change -66.63% -83.63% -67.17%
SHAREHOLDERS EQUITY
Retained Earnings -$33.40M -$32.17M
YoY Change
Common Stock $202.5K $201.1K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.816M $10.70M $11.75M
YoY Change
Total Liabilities & Shareholders Equity $13.05M $12.03M $13.33M
YoY Change -5.95% -12.31% 62.3%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.228M -$1.430M -$2.152M
YoY Change -48.25% -48.35% 105.58%
Depreciation, Depletion And Amortization $21.84K $21.83K $21.83K
YoY Change 0.05%
Cash From Operating Activities -$885.0K -$1.337M -$1.631M
YoY Change -13.36% -15.5% 249.9%
INVESTING ACTIVITIES
Capital Expenditures -$33.86K -$135.3K -$8.640K
YoY Change -74.92%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$618.8K
YoY Change -100.0% -100.0% 255.65%
Cash From Investing Activities -$33.86K -$135.3K -$627.5K
YoY Change -82.32% -94.11% 260.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.861M 66.15K 80.21K
YoY Change 82.53% -98.19% -91.75%
NET CHANGE
Cash From Operating Activities -885.0K -1.337M -1.631M
Cash From Investing Activities -33.86K -135.3K -627.5K
Cash From Financing Activities 1.861M 66.15K 80.21K
Net Change In Cash 941.7K -1.406M -2.179M
YoY Change -586.01% 511.14% -757.06%
FREE CASH FLOW
Cash From Operating Activities -$885.0K -$1.337M -$1.631M
Capital Expenditures -$33.86K -$135.3K -$8.640K
Free Cash Flow -$851.1K -$1.202M -$1.623M
YoY Change -3.99% 248.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2188032 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5772839 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
66841 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
757383 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
2254873 usd
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
201478332 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56155
dei Entity Registrant Name
EntityRegistrantName
CRYOMASS TECHNOLOGIES INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5051728
dei Entity Address Address Line1
EntityAddressAddressLine1
1001 Bannock Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 612
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80204
dei City Area Code
CityAreaCode
303
dei Local Phone Number
LocalPhoneNumber
416-7208
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
799796 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
238432 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
6530222 usd
CY2022Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Noncurrent
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent
4218831 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Noncurrent
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossNoncurrent
3600000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
349586 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
225000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4014261 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4038600 usd
CY2022Q2 us-gaap Goodwill
Goodwill
1190000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
1190000 usd
CY2022Q2 us-gaap Assets
Assets
12027551 usd
CY2021Q4 us-gaap Assets
Assets
15583822 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1089059 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1882419 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1089059 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1882419 usd
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
239583 usd
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
177083 usd
CY2022Q2 us-gaap Liabilities
Liabilities
1328642 usd
CY2021Q4 us-gaap Liabilities
Liabilities
2059502 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
201051665 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
201051665 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
196949801 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
196949801 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
201053 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
196950 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42589208 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41916207 usd
CY2022Q2 crym Common Stock To Be Issued
CommonStockToBeIssued
80208 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32171560 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28588837 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10698909 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13524320 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12027551 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15583822 usd
CY2022Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
466422 usd
CY2021Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
426082 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
801652 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1979337 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
533781 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2375807 usd
CY2022Q2 us-gaap Legal Fees
LegalFees
688194 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2769639 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3582723 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3816566 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
usd
CY2021Q2 us-gaap Legal Fees
LegalFees
232026 usd
us-gaap Legal Fees
LegalFees
2146451 usd
us-gaap Legal Fees
LegalFees
457546 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
21831 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
43663 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1365 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18487 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1416244 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
2637445 usd
us-gaap Operating Expenses
OperatingExpenses
3544034 usd
us-gaap Operating Expenses
OperatingExpenses
3633149 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
200596549 shares
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.03
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1416244 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2637445 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3544034 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3633149 usd
CY2022Q2 crym Non Operating Interest Expense
NonOperatingInterestExpense
35235 usd
CY2021Q2 crym Non Operating Interest Expense
NonOperatingInterestExpense
359648 usd
crym Non Operating Interest Expense
NonOperatingInterestExpense
71258 usd
crym Non Operating Interest Expense
NonOperatingInterestExpense
562257 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
21061 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-11232 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
32569 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
23538 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14174 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-370880 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-38689 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-538719 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1430418 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3008325 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3582723 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4171868 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-1430418 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3008325 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3582723 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-4171868 usd
CY2021Q2 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
-238686 usd
us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
-355302 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1430418 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-2769639 usd
us-gaap Profit Loss
ProfitLoss
-3582723 usd
us-gaap Profit Loss
ProfitLoss
-3816566 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1430418 usd
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.04
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106008685 shares
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-690542 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
200164004 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102176247 shares
crym Payoff Of Cryo Cann Loan Agreement At Closing
PayoffOfCryoCannLoanAgreementAtClosing
1247684 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
618831 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3605294 usd
CY2021Q1 crym Share Issuance For Interest Payment On Note Payable
ShareIssuanceForInterestPaymentOnNotePayable
110000 usd
CY2021Q1 crym Stockbased Compensation Options
StockbasedCompensationOptions
250817 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1046927 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2919184 usd
CY2021Q2 crym Share Issuance For Interest Payment On Note Payable
ShareIssuanceForInterestPaymentOnNotePayable
202 usd
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1804500 usd
CY2021Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
900701 usd
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
508402 usd
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
57500 usd
CY2021Q2 crym Stockbased Compensation Options
StockbasedCompensationOptions
190026 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
710202 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
391958 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
888371 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2769239 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
5601407 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13524320 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
240625 usd
CY2022Q1 crym Stockbased Compensation Options
StockbasedCompensationOptions
140815 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2152305 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11753455 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66151 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
240626 usd
CY2022Q2 crym Stockbased Compensation Options
StockbasedCompensationOptions
69095 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1430418 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10698909 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3582723 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4171868 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
62500 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
251282 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
43663 usd
us-gaap Share Based Compensation
ShareBasedCompensation
209910 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2074547 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
401044 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
27200 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-40475 usd
crym Accounts Payable And Accrued Expense
AccountsPayableAndAccruedExpense
793360 usd
crym Accounts Payable And Accrued Expense
AccountsPayableAndAccruedExpense
-182574 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2968424 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1595790 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-452828 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2968424 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2048618 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
124586 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
19325 usd
crym Carrying Value Of Goodwill
CarryingValueOfGoodwill
1190000 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-762742 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2247684 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-224003 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-762742 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2471687 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
66151 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
120000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
80208 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-412359 usd
crym Proceeds From Notes Payable Current
ProceedsFromNotesPayableCurrent
4690000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
281771 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
146359 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4115870 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
505902 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
146359 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4621772 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-3584807 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
272396 usd
us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
-170929 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5772839 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
329839 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2188032 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
431306 usd
us-gaap Interest Paid Net
InterestPaidNet
171604 usd
crym Common Stock Issued Pursuant To Vesting Of Restricted Stock Units
CommonStockIssuedPursuantToVestingOfRestrictedStockUnits
290000 usd
crym Common Stock Issued Pursuant To Vesting Of Restricted Stock Units
CommonStockIssuedPursuantToVestingOfRestrictedStockUnits
2940603 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Nature of the Business</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cryomass Technologies Inc (“Cryomass Technologies” or the “Company”) designs, manufactures and is developing the strategy to commercialize patented cryo-mechanical systems for the harvesting and refinement of hemp, cannabis, and potentially other high value crops such as hops. The system exploits CryoMass’s U.S.-patented process for the controlled application of liquid nitrogen to stabilize and separate the structural elements of gross plant material. The device currently under development can be operated at a cultivation site or be installed at a processing facility and is being optimized for the collection of fully intact hemp and cannabis trichomes. The first functional “beta” machine has been through a first phase of testing field-. The first commercial unit is expected to be delivered to an operating partner’s facility by the end of the third quarter 2022.</p>
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Averages Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAveragesGrantDateFairValue
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Variable Interest Difference Between Carrying Amount And Maximum Exposure
VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure
3600000 usd
CY2021 us-gaap Variable Interest Entity Qualitative Or Quantitative Information Date Involvement Began1
VariableInterestEntityQualitativeOrQuantitativeInformationDateInvolvementBegan1
2023-12-31
CY2022Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.12 pure
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
24500000 shares
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
0.4
CY2022Q2 crym Working Capital
WorkingCapital
1165814 usd
CY2022Q2 us-gaap Cash
Cash
2188032 usd
us-gaap Retail Land Sales Estimated Cost Of Major Improvements
RetailLandSalesEstimatedCostOfMajorImprovements
4000000 usd
CY2022Q2 us-gaap Other Additional Capital
OtherAdditionalCapital
500000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1000000 usd
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
225000 usd
crym Facility Limit
FacilityLimit
10000000 usd
crym Cash For Operating Activities
CashForOperatingActivities
2968424 usd
us-gaap Malpractice Loss Contingency Claims Incurred Net
MalpracticeLossContingencyClaimsIncurredNet
3582723 usd
CY2022Q2 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
32171560 usd
CY2021 crym Carrying Value Of Goodwill
CarryingValueOfGoodwill
1190000 usd
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
72917 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Reclassifications</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain items in the interim condensed consolidated financial statements were reclassified from prior periods for presentation purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Additionally, the company entered into a $3,600,000 loan receivable in conjunction with the disposal of discontinued operations at the end of 2021, which is backed by the assets of the discontinued operations, should the borrower default. Aside from these items, the Company does not believe it is exposed to any unusual credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
3600000 usd
CY2021Q4 us-gaap Long Term Debt Maturity Date
LongTermDebtMaturityDate
2022-08-01
CY2021Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.936 pure
CY2021Q4 crym Indefinite Lived Intangible Assets Accumulated Amortization Excluding Goodwill
IndefiniteLivedIntangibleAssetsAccumulatedAmortizationExcludingGoodwill
-43663 usd
CY2021Q2 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3500000000000 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Share Based Compensation Gross
StockIssuedDuringPeriodSharesShareBasedCompensationGross
10000000 shares
CY2021Q4 crym Promissory Note Issued
PromissoryNoteIssued
1252316 usd
CY2021Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
2500000 usd
crym Income Taxes Description
IncomeTaxesDescription
In accordance with ASC 740-10, for those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, our policy will be to record the largest amount of tax benefit that is more likely than not to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit will be recognized in the condensed consolidated financial statements.
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
928779 usd
crym Conversion Of Warrants
ConversionOfWarrants
515763 usd
CY2022Q2 us-gaap Notes Payable
NotesPayable
1444542 usd
crym Debt Instrument Amortized Discount
DebtInstrumentAmortizedDiscount
188782 usd
crym Debt Instrument Amortized Discount
DebtInstrumentAmortizedDiscount
188782 usd
crym Unvested Of Shares Restricted Stock Potentially Dilutive Securities Outstanding
UnvestedOfSharesRestrictedStockPotentiallyDilutiveSecuritiesOutstanding
1258982 shares
crym Unvested Of Shares Restricted Stock Potentially Dilutive Securities Outstanding
UnvestedOfSharesRestrictedStockPotentiallyDilutiveSecuritiesOutstanding
2185000 shares
CY2021Q2 us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
3008325 usd
us-gaap Business Combination Separately Recognized Transactions Net Gains And Losses
BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses
5034172 usd
CY2021Q2 us-gaap Extinguishment Of Debt Gain Loss Per Share Net Of Tax
ExtinguishmentOfDebtGainLossPerShareNetOfTax
0.03
us-gaap Extinguishment Of Debt Gain Loss Per Share Net Of Tax
ExtinguishmentOfDebtGainLossPerShareNetOfTax
0.05
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
4082263 usd
CY2022Q2 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
349586 usd
CY2021Q4 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
225000 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
349586 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
225000 usd
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
4101588 usd
CY2022Q2 crym Indefinite Lived Intangible Assets Accumulated Amortization Excluding Goodwill
IndefiniteLivedIntangibleAssetsAccumulatedAmortizationExcludingGoodwill
-87327 usd
CY2022Q2 crym Indefinitelived Intangible Assets Impairment
IndefinitelivedIntangibleAssetsImpairment
4014261 usd
CY2021Q4 crym Indefinitelived Intangible Assets Impairment
IndefinitelivedIntangibleAssetsImpairment
4038600 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21833 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
43663 usd
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2021 us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
3600000 usd
CY2022Q1 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
620000 usd
CY2020Q3 us-gaap Debt Instrument Description
DebtInstrumentDescription
The 1) convertible note has a face value of $250,000, matures August 1, 2022, and accrues interest at 8% per annum.
CY2022Q2 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
239583 usd
CY2022Q2 us-gaap Convertible Debt
ConvertibleDebt
250000 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
10417 usd
CY2021Q4 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
177083 usd
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
250000 usd
CY2021Q1 us-gaap Debt Instrument Repurchase Date
DebtInstrumentRepurchaseDate
2021-04-27
CY2021Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
225000 usd
CY2021Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.15 pure
CY2021Q1 us-gaap Debt Instrument Repurchase Date
DebtInstrumentRepurchaseDate
2021-05-07
CY2021Q3 crym Loans Agreement
LoansAgreement
300000 usd
CY2021Q3 us-gaap Short Term Debt Percentage Bearing Fixed Interest Rate
ShortTermDebtPercentageBearingFixedInterestRate
0.9123 pure
CY2021Q3 crym Debt Instruments Maturity Date
DebtInstrumentsMaturityDate
May 27, 2021
CY2021Q3 us-gaap Debt Instrument Repurchase Date
DebtInstrumentRepurchaseDate
2021-10-19
us-gaap Operating Lease Payments
OperatingLeasePayments
30516 usd
CY2022Q2 crym Present Value Of Liabilities Increased Decreased By Business Acquisition
PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition
0 usd
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstandingNumber
0.27
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
510000 shares
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Grant In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueGrantInPeriod
0.35
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1135000 shares
crym Note Receivable Issued Amount
NoteReceivableIssuedAmount
281771 usd
CY2021Q3 crym Loan Agreement
LoanAgreement
237590 usd
CY2021Q4 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.14 pure
CY2021Q4 crym Excess Stock Shares Issued1
ExcessStockSharesIssued1
250000 shares
CY2021Q4 us-gaap Memberships In Exchanges Owned
MembershipsInExchangesOwned
50000 usd
CY2021Q2 crym Issuance Of Common Stock Shares
IssuanceOfCommonStockShares
10000000 shares
CY2021Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6903172 shares
CY2021Q2 crym Agreements Shares
AgreementsShares
2500000 shares
CY2021Q2 crym Share Exchange For Services
ShareExchangeForServices
633125 shares
CY2021Q3 crym Common Stock Shares
CommonStockShares
798414 shares
CY2021Q3 us-gaap Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares
StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
633707 shares
CY2021Q3 crym Interest Rate
InterestRate
92127 shares
CY2021Q4 crym Common Stock Shares
CommonStockShares
50700000 shares
CY2021Q4 crym Common Stock In Exchange For Services
CommonStockInExchangeForServices
1570501 shares
CY2021Q4 crym Common Stock In Exchange For Extinguishment Of Debt
CommonStockInExchangeForExtinguishmentOfDebt
24621119 shares
CY2022Q1 crym Common Stock Shares
CommonStockShares
458334 shares
CY2022Q1 crym Common Stock In Exchange For Services
CommonStockInExchangeForServices
550000 shares
CY2022Q1 crym Common Stock In Exchange For Extinguishment Of Debt
CommonStockInExchangeForExtinguishmentOfDebt
185529 shares
CY2022Q1 crym Common Stock Shares
CommonStockShares
1000000 shares
CY2022Q2 crym Share Exchange For Services
ShareExchangeForServices
687501 shares
CY2022Q2 crym Common Stock Shares
CommonStockShares
1000000 shares
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
220500 shares
CY2021Q4 crym Share Based Compensation Arrangement By Share Based Restricted Stock Payment Award Number
ShareBasedCompensationArrangementByShareBasedRestrictedStockPaymentAwardNumber
2200003 shares
CY2021Q4 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstandingNumber
0.45
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1469511 shares
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Grant In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueGrantInPeriod
0.27
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1735529 shares
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Payment Award Option Vested Weighted Average Grants Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedWeightedAverageGrantsDateFairValue
0.49
CY2022Q1 crym Share Based Compensation Arrangement By Share Based Restricted Stock Payment Award Number
ShareBasedCompensationArrangementByShareBasedRestrictedStockPaymentAwardNumber
1933985 shares
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Payment Award Option Vested Weighted Average Grants Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedWeightedAverageGrantsDateFairValue
0.28
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50000 shares
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Averages Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAveragesGrantDateFairValue
0.17
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Restricted Stock Payment Award Number
ShareBasedCompensationArrangementByShareBasedRestrictedStockPaymentAwardNumber
1258985 shares
CY2022Q2 crym Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grant Date Fair Value Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantDateFairValueOutstandingNumber
0.2
CY2022Q2 us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
317000 usd
us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
1165600 usd
CY2021Q2 crym Fair Value Of Rs Us Vested
FairValueOfRSUsVested
900000 usd
crym Fair Value Of Rs Us Vested
FairValueOfRSUsVested
3046602 usd
crym Unrecognized Stock Based Compensation
UnrecognizedStockBasedCompensation
274241 usd
CY2021Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
6135000 shares
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
6635000 shares
CY2021Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
73950000 shares
CY2021 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.4
CY2022Q2 crym Warrant Share Issued
WarrantShareIssued
220500 shares
crym Warrant Share Issued
WarrantShareIssued
220500 shares
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.3
CY2022Q2 crym Fair Value Of Additional Paid In Capital
FairValueOfAdditionalPaidInCapital
1867960 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
crym Other Lease Term
OtherLeaseTerm
P12M
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
16124 usd
CY2021Q2 crym Present Value Of Liabilities Increased Decreased By Business Acquisition
PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition
81218 usd
crym Present Value Of Liabilities Increased Decreased By Business Acquisition
PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition
0 usd
crym Present Value Of Liabilities Increased Decreased By Business Acquisition
PresentValueOfLiabilitiesIncreasedDecreasedByBusinessAcquisition
213448 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
0 usd
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
166509 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
0 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
326034 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001533030
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
CY2022Q2 us-gaap Revenues
Revenues
usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
usd
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
usd
us-gaap Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses
DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
200596549 shares
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
usd
crym Payoff Of Cryo Cann Loan Agreement At Closing
PayoffOfCryoCannLoanAgreementAtClosing
usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
usd
crym Proceeds From Notes Payable Current
ProceedsFromNotesPayableCurrent
usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
usd
us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
usd

Files In Submission

Name View Source Status
0001213900-22-046798-index-headers.html Edgar Link pending
0001213900-22-046798-index.html Edgar Link pending
0001213900-22-046798.txt Edgar Link pending
0001213900-22-046798-xbrl.zip Edgar Link pending
crym-20220630.xsd Edgar Link pending
f10q0622ex31-1_cryomasstech.htm Edgar Link pending
f10q0622ex31-2_cryomasstech.htm Edgar Link pending
f10q0622ex32-1_cryomasstech.htm Edgar Link pending
f10q0622ex32-2_cryomasstech.htm Edgar Link pending
crym-20220630_def.xml Edgar Link unprocessable
crym-20220630_lab.xml Edgar Link unprocessable
crym-20220630_cal.xml Edgar Link unprocessable
crym-20220630_pre.xml Edgar Link unprocessable
f10q0622_cryomasstech.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
f10q0622_cryomasstech_htm.xml Edgar Link completed
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable